The PERSEPHONE trial: 6 months and 12 months of trastuzumab in breast cancer

Bookmark and Share
Published: 7 Aug 2018
Views: 1880
Prof Mariana Chavez-McGregor - University of Texas MD Anderson Cancer Center, Houston, USA

Prof Chavez-McGregor speaks to ecancer at BEST OF ASCO® 2018 MIAMI SYMPOSIUM about the PERSEPHONE trial.

PERSEPHONE studies whether women with early breast cancer can safely have trastuzumab for 6 months instead of 12.

Prof Chavez-McGregor describes how the results are generally positive, but also touches upon the drawbacks of the study.